coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Bognor Coastal Alliance PCN, Arun · Health Inequalities Profile

    PCN U60757 · NHS Surrey and Sussex Integrated Care Board; NHS Sussex Integrated Care Board · 3 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    36,731

    Registered population

    54.4% aged 18–64

    29.6%

    Aged 65+

    ICB 21.9% · England 17.9%

    4.5%

    Ethnic minority (non-White)

    1.8% Asian · England 9.6%

    9.4%

    In IMD quintile 1

    ICB 9.2% · England 21.0%

    ~3,081

    Core20 residents (est.)

    Resident basis; registered basis ~3,278 · see page 3

    7,368

    Hypertension register

    +3.54% in 3 yrs · England +5.60%

    478

    SMI register

    23.9% of Arun's

    1,053

    COPD register

    Reviews -3.92% in 3 yrs

    Forecast to 2030

    8,286

    Hypertension patients, 2030

    +918 on today

    71.2%

    QRISK ≥20% on statins, 2030

    +5.69pp over 3 yrs

    6.4%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    59.8%
    Asthma annual reviews lag and declined.

    Asthma reviews are 59.8% (England 65.7%) after a -6.9% three-year change (England +4.4%), leaving 1,174 patients unreviewed; this may reflect recall gaps, unverified locally.

    57.9%
    High-risk lipid therapy lags despite higher unit costs.

    Lipid therapy is 57.9% for QRISK ≥ 20% (England 63.6%) and 61.7% for CKD (England 70.3%), while items cost £3.20 (England £1.86).

    72.7%
    Hypertension blood pressure control exceeds benchmarks.

    Hypertension prevalence is 19.9% (England 15.2%), yet blood pressure control reaches 72.7%, above Arun (68.8%), the ICB (69.1%) and England (70.3%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Patients aged 65+ comprise 29.6% of the list, well above England

    Across 36,731 registered patients, 29.6% (10,885 patients) are aged 65+, above Arun (29.2%), NHS Sussex Integrated Care Board (21.9%), and England (17.9%). Working-age adults (18-64) make up 54.4% (19,981 patients), below Arun (54.9%), the ICB (60.5%), and England (62.7%), while aged 0-17 comprise 16.0% (5,865 patients). Registered list size is projected to grow 3.3% by 2030 (Arun 2.7%; ICB 2.1%; England 2.3%; unverified methodology). Census resident data show 95.5% White ethnicity (Arun 95.8%; ICB 91.0%; England 81.1%), with 4.5% ethnic minorities; these describe local residents rather than registered patients.

    Age profile

    0–1716.0%
    18–6454.4%
    65+29.6%

    65+: ICB 21.9%, England 17.9%

    Ethnicity

    White95.5%
    Asian1.8%
    Mixed1.4%
    Other0.9%
    Black0.5%

    Older people · falls rows are Arun local-authority (LA) data, not PCN

    MeasureLocalSouth EastEnglandPeriod
    Falls admissions, 65+, per 100,000 (Arun LA)2,3272,0181,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)80.4%82.2%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)58.8%57.8%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Arun LA)1,2169819552024/25
    Falls deaths, all ages, per 100,000 (Arun LA)13.314.014.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation is 9.4% overall but reaches 16.1% at Maywood Health Care Centre

    The PCN Core20 share is 9.4%, below England (21.0%) and Arun (9.8%) but in line with NHS Sussex Integrated Care Board (9.2%), with an average IMD decile of 5.5. Weighted practice share is 8.9%, reflecting different source bases. Deprivation concentrates in Maywood Health Care Centre with a 16.1% share (an estimated 2,849 patients), while West Meads Surgery has 5.5% (429 patients) and Grove House Surgery has 0.0%. Associated LSOAs contain an estimated 3,081 residents across deciles 1 and 2. Observation periods are unconfirmed.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Maywood Health16.1% · 2,849 patients
    West Meads5.5% · 429 patients
    Grove House0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    478

    SMI register

    1.29% recorded prevalence

    362

    Learning disability register

    0.98% recorded prevalence

    38

    Care homes, 941 beds

    In the PCN catchment

    8.9%

    Provide unpaid care

    Arun, Census 2021

    The PCN records 362 learning disability patients (1.0%; Arun 0.8%, NHS Sussex Integrated Care Board 0.6%, England 0.6%) and 478 severe mental illness patients (1.3%; Arun 1.1%, NHS Sussex Integrated Care Board 1.1%, England 1.0%). The catchment contains 38 care homes (941 beds). Modelled ceiling estimates indicate about 3,300 unpaid carers, though practice counts were not captured.

    Severe mental illness: physical health checks

    SMI prevalence is 1.3% (478 patients). Recorded blood pressure checks reach 79.9% (England 83.4%) and BMI recording reaches 81.6% (England 82.1%). Cardiovascular monitoring for SMI patients lags national rates, indicating an opportunity to tighten annual physical health recall.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    7,368

    Hypertension register

    +3.54%

    Register growth, 3 yrs

    Arun +4.55% · England +5.60%

    +3.27pp

    BP control, under 80

    ≤140/90 · +0.01pp aged 80+

    +918

    More patients by 2030

    Forecast 8,286 (21.37%)

    Hypertension case-finding and control

    Hypertension prevalence is 19.9% (7,368 patients), above England (15.2%), Arun (19.8%) and NHS Sussex Integrated Care Board (16.3%), which is consistent with an older population where 29.6% are aged 65+. Blood pressure treated to target is 72.7%, exceeding England (70.3%), Arun (68.8%) and the ICB (69.1%). For patients aged under 80, control reaches 69.7% (England 67.8%), though Maywood Health Care Centre records 66.2%. Recent blood pressure readings reached 89.2% (England 90.0%), with three-year growth of +1.4% trailing England (+3.6%). Crude register prevalence does not establish undiagnosed disease. Strong overall blood pressure control alongside trailing monitoring growth suggests systematic recall could sustain management across the expanding older cohort.

    Lipids and statins

    Lipid-lowering therapy lags England across high-risk groups: QRISK ≥ 20% is 57.9% (England 63.6%), CKD is 61.7% (England 70.3%), and diabetes without CVD is 68.7% (England 73.2%). Fewer at-risk patients receive lipid-lowering therapy than national rates imply, so a targeted recall of eligible primary prevention cohorts is the key opportunity.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202669,004£3.20£2.42£1.86£220,813
    Cardiovascular (all), 202591,552£4.25£3.32£3.33£389,096

    For lipid-modifying drugs in 2026, the PCN prescribed 69,004 items at £3.20 per item, spending £92,465 more than at England's unit cost (£1.86; NHS Sussex Integrated Care Board £2.42). Unit cost does not reflect clinical appropriateness. Spending more per item than comparators while treatment rates trail national levels highlights an opportunity to review formulary choices and statin initiation.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −6.88%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −0.22%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 8.2% (2,919 patients; England 6.6%) and COPD is 2.9% (1,053 patients; England 1.9%). Over 2023 to 2025, annual reviews fell -6.9% for asthma to 59.8% (England +4.4%; 65.7%), leaving an estimated 1,174 patients unreviewed, and -3.9% for COPD to 70.5% (England +2.8%; 76.4%). Youth asthma prescribing is 2,059 per 1,000 (England 1,488) and second-hand smoking recording is 70.8% (England 78.8%). Falling review rates alongside high youth prescribing may reflect recall gaps, unverified locally.

    Cancer register and children's immunisation

    Cancer register prevalence is 5.7% (2,118 patients; England 3.8%). In Q1 2025/26, age-5 coverage reaches 96.2% for MMR dose 1, but drops 6.3 pp to 89.9% for MMR dose 2 (England 82.8%), sitting below the 95.0% target by 5.1 pp. Pre-school 4-in-1 booster coverage also matches 89.9% (England 80.9%). Second-dose drop may reflect recall gaps, which clinical audit would test.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months94.3%

    England 91.0%

    6-in-1 complete primary course at 24 months94.7%

    England 92.2%

    MMR dose 1 at 24 months90.7%

    England 88.3%

    MMR dose 2 at age 589.9%

    England 82.8%

    4-in-1 pre-school booster at age 589.9%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    58.5%

    Sussex ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~1,360

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Sussex ICBEnglandNo usable stageStaged cancers
    Prostate56.6%53.2%19%1,668
    Breast86.1%85.4%23%1,400
    Bowel49.8%47.0%26%1,133
    Lung30.3%33.8%15%1,058
    Skin cancer95.3%87.8%17%698

    In 2022, 58.5% of staged cancers (4,799 of 8,209 with known stage) across NHS Sussex ICB were diagnosed at stage 1 or 2, above England (55.3%) but below the 75.0% national ambition by 16.5 pp, an ICB gap of about 1,360 early-stage cases. Known stage was recorded for 64.3% of registered cancers (8,209 of 12,766). These ICB figures describe the wider system, not PCN performance. At PCN level, recorded cancer prevalence is 5.7% (2,118 patients). Cervical screening coverage is 69.5% (England 66.8%) but fell 2.4% over three years (England -1.0%), while breast screening coverage fell 2.0% to 69.3% (England +8.4%).

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the cancer 62-day standard, trailing University Hospital Southampton NHS Foundation Trust (74.4%), Portsmouth Hospitals University NHS Trust (75.2%), NHS Surrey and Sussex Integrated Care Board (71.5%), and England (71.2%), falling below the 85.0% standard by 19.8 pp. The 28-day faster diagnosis standard reached 74.0% (England 79.3%). For all diagnostic tests, 12.9% waited 6+ weeks (England 23.1%), though colonoscopy waits reached 39.3% (England 30.8%). These provider and ICB waiting times describe the wider system, not PCN performance.

    Pathways within standard (%)SussexPortsmouthSouthamptonSurrey and Sussex ICBEngland
    28-day faster diagnosis (75%)74.0166.8175.0779.2979.32
    31-day treatment (96%)76.7994.7886.7690.4592.50
    62-day referral to treatment (85%)65.2075.2074.4471.5171.16
    Diagnostic waits over 6 weeks (%)SussexPortsmouthSouthamptonEngland
    MRI5.6250.3614.3021.40
    CT8.5713.0616.479.92
    Echocardiography0.3932.7514.5828.48
    Colonoscopy39.3582.5215.8430.83
    Gastroscopy20.0274.8818.4729.02
    All 15 DM01 tests12.9551.9620.8423.14
    Community services activityWest Sussex residentsSurrey and Sussex ICB
    Care contacts78,050309,615
    Referrals16,01566,930
    Patients with a contact19,77085,660

    Community services (residents of West Sussex), Jun 2026 (provisional). In June 2026, West Sussex recorded 78,050 community care contacts across 19,770 patients, with adults aged 65+ accounting for 72.7% of contacts (56,740). NHS Surrey and Sussex Integrated Care Board recorded 309,615 contacts across 85,660 patients. These provisional figures describe local authority and system activity rather than PCN performance, though 29.6% of the PCN's registered list is aged 65+.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Overall QOF reaches at least 97.2% across practices, while vaccination varies by 14.7 pp

    In 2025/26, overall QOF achievement exceeded England's 92.5% across all three practices: Grove House Surgery reached 99.3%, Maywood Health Care Centre reached 97.9%, and West Meads Surgery reached 97.2%. In contrast, vaccination and immunisation domain achievement spanned 14.7 pp: Grove House Surgery achieved 94.2%, Maywood Health Care Centre achieved 81.8%, and West Meads Surgery achieved 79.5%.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Maywood Health9616.171.0%54.5%86.2%
    West Meads Surgery1045.571.2%79.3%80.2%
    Grove House1040.059.3%71.8%76.3%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNArunAssetPCNArun
    Care homes (catchment)38 (941 beds)n/aSchools (catchment)18n/a
    Children's centres27Places of worship1568
    Libraries27Homelessness support (VCS)0no data
    Day centres (VCS)n/a1Carers support groups (VCS)n/a1
    Primary schools (LA maintained)721Primary academies719
    Special schoolsn/a1

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured respiratory recall and inhaler review

    Asthma reviews fell 6.9% over 2023 to 2025 to 59.8% (England 65.7%, +4.4%), leaving 1,174 of 2,919 patients unreviewed; COPD reviews fell 3.9% to 70.5% (England 76.4%, +2.8%). For discussion: run a single-template respiratory recall with after-school slots for children, combining inhaler prescribing and smoking checks. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    High-risk lipid initiation and formulary review

    Lipid therapy lags England for QRISK ≥ 20% at 57.9% (England 63.6%), CKD at 61.7% (70.3%), and diabetes at 68.7% (73.2%); 69,004 items at £3.20 cost £92,465 more than England's £1.86 unit cost. For discussion: pair hypertension reviews with a pharmacist search for untreated high-risk cohorts alongside a formulary review. Moderate effort to run.

    Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.

    Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.

    Option 3

    Pre-school MMR and booster recall

    In Q1 2025/26, age-5 MMR dose 2 and 4-in-1 booster coverage are both 89.9% (cohort 79; England 82.8% and 80.9%), below the 95.0% target by 5.1 pp and down 6.3 pp from dose 1 (96.2%). Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older population care coordination (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Targeted Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical health recall audit (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension monitoring recall audit (p5)Hypertension patients with a recent blood pressure readingCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall outreach (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Screening recall protocol review (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)—PCN
    Online access review (p9)GPPS easy to contact the practice using its website10YHP, hospital to communityPractice
    Option 1 · Structured respiratory recall and inhaler review (p12)Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · High-risk lipid initiation and formulary review (p12)Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Pre-school MMR and booster recall (p12)MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% target · Core20PLUS5 · 10YHP equity testPCN & Practice
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15